Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world ranibizumab treatment patterns and effectiveness in China
ChiCTR1900022891Phase 4Recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Oct 2018
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in exudative macular degeneration, diabetic macular edema (DME) and Vein occlusion (RVO), sponsored by Zhongshan Ophthalmic Center. Primary endpoints: Number of ranibizumab injections at Month 24, Number of other intraocular injections at Month 24 and 3 more. Started Oct 2018; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)Vein occlusion (RVO)
Beyond the preview
Go deeper on ChiCTR1900022891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022891.